journal article·2024-03-11

A One-Stone-Two-Birds Strategy of Targeting Microbubbles with “Dual” Anti-Inflammatory and Blood–Brain Barrier “Switch” Function for Ischemic Stroke Treatment

Zhongbin An, Qiong He, Ling Jiang, Yuan Wang, Yongyue Zhang, Yang Sun, Mengxin Wang, Shiyuan Yang, Lijie Huang, Huiwen Li, Yu Hao, Xiaolong Liang, Shumin Wang

Publisher page

Abstract

Inflammation is considered to be the main target of the development of new stroke therapies. There are three key issues in the treatment of stroke inflammation: the first one is how to overcome the blood-brain barrier (BBB) to achieve drug delivery, the second one is how to select drugs to treat stroke inflammation, and the third one is how to achieve targeted drug delivery. In this study, we constructed hydrocortisone-phosphatidylserine microbubbles and combined them with ultrasound (US)-targeted microbubble destruction technology to successfully open the BBB to achieve targeted drug delivery. Phosphatidylserine on the microbubbles was used for its "eat me" effect to increase the targeting of the microvesicles. In addition, we found that hydrocortisone can accelerate the closure of the BBB, achieving efficient drug delivery while reducing the entry of peripheral toxins into the brain. In the treatment of stroke inflammation, it was found that hydrocortisone itself has anti-inflammatory effects and can also change the polarization of microglia from the harmful pro-inflammatory M1 phenotype to the beneficial anti-inflammatory M2 phenotype, thus achieving dual anti-inflammatory effects and enhancing the anti-inflammatory effects in ischemic areas after stroke, well reducing the cerebellar infarction volume by inhibiting the inflammatory response after cerebral ischemia. A confocal microendoscope was used to directly observe the polarization of microglial cells in living animal models for dynamic microscopic visualization detection showing the advantage of being closer to clinical work. Taken together, this study constructed a multifunctional targeted US contrast agent with the function of "one-stone-two-birds", which can not only "on-off" the BBB but also have "two" anti-inflammatory functions, providing a new strategy of integrated anti-inflammatory targeted delivery and imaging monitoring for ischemic stroke treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Photoacoustic and Ultrasonic Imaging · Vagus Nerve Stimulation Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Ultrasound, Peking University Third Hospital, Beijing 100191, China

Ordos Central Hospital, Ordos, Inner Mongolia 017000, China

Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing 100084, China

Tsinghua-Peking Joint Center for Life Sciences, Tsinghua University, Beijing 100084, China

Tsinghua University, Hai Dian, Beijing 017000, China

Funding

National Natural Science Foundation of China · Innovation Transformation Special Project of Haidian · peking University Third Hospital Cohort Construction Project

References (78)

Show source-provided references
1. 10.1001/jamaneurol.2018.107310.1001/jamaneurol.2018.1073 ↗
2. 10.1161/STROKEAHA.117.01707310.1161/STROKEAHA.117.017073 ↗
3. 10.1002/adfm.20220940510.1002/adfm.202209405 ↗
4. 10.1016/j.jacc.2016.03.55510.1016/j.jacc.2016.03.555 ↗
5. 10.3892/mmr.2020.1100310.3892/mmr.2020.11003 ↗
6. 10.1182/blood-2021-15142310.1182/blood-2021-151423 ↗
7. 10.1016/j.addr.2022.11448510.1016/j.addr.2022.114485 ↗
8. 10.1016/j.copbio.2019.01.01310.1016/j.copbio.2019.01.013 ↗
9. 10.1002/adma.20180136210.1002/adma.201801362 ↗
10. 10.1016/j.pneurobio.2016.05.00110.1016/j.pneurobio.2016.05.001 ↗
11. 10.1111/cns.1257510.1111/cns.12575 ↗
12. 10.3389/fncel.2017.0015410.3389/fncel.2017.00154 ↗
13. 10.1038/s41419-019-1716-910.1038/s41419-019-1716-9 ↗
14. 10.1007/s00011-016-0939-910.1007/s00011-016-0939-9 ↗
15. 10.4049/jimmunol.130349210.4049/jimmunol.1303492 ↗
16. 10.1080/01616412.2016.118847310.1080/01616412.2016.1188473 ↗
17. 10.3389/fnmol.2017.0039810.3389/fnmol.2017.00398 ↗
18. 10.1161/STROKEAHA.115.01207910.1161/STROKEAHA.115.012079 ↗
19. 10.1007/s10571-019-00675-710.1007/s10571-019-00675-7 ↗
20. 10.1523/JNEUROSCI.1685-15.201510.1523/JNEUROSCI.1685-15.2015 ↗
21. 10.1016/j.biopha.2018.05.14310.1016/j.biopha.2018.05.143 ↗
22. 10.1016/j.brainres.2018.11.01910.1016/j.brainres.2018.11.019 ↗
23. 10.1161/STROKEAHA.115.01009110.1161/STROKEAHA.115.010091 ↗
24. 10.1089/neu.2017.554010.1089/neu.2017.5540 ↗
25. 10.1016/j.biopha.2019.10910210.1016/j.biopha.2019.109102 ↗
26. 10.1186/s12974-018-1081-010.1186/s12974-018-1081-0 ↗
27. 10.3389/fphys.2018.0052910.3389/fphys.2018.00529 ↗
28. 10.1016/j.ajps.2017.05.00610.1016/j.ajps.2017.05.006 ↗
29. 10.1038/nrneurol.2017.6910.1038/nrneurol.2017.69 ↗
30. 10.1016/j.expneurol.2015.08.01810.1016/j.expneurol.2015.08.018 ↗
31. 10.1007/s12264-019-00388-310.1007/s12264-019-00388-3 ↗
32. 10.1016/j.ajps.2016.12.00110.1016/j.ajps.2016.12.001 ↗
33. 10.1016/j.neuint.2019.03.02210.1016/j.neuint.2019.03.022 ↗
34. 10.1016/j.pneurobio.2016.01.00510.1016/j.pneurobio.2016.01.005 ↗
35. 10.1523/JNEUROSCI.3696-05.200610.1523/JNEUROSCI.3696-05.2006 ↗
36. 10.1016/j.pneurobio.2010.08.00110.1016/j.pneurobio.2010.08.001 ↗
37. 10.1111/cns.1308110.1111/cns.13081 ↗
38. 10.2174/138945012066619101711473510.2174/1389450120666191017114735 ↗
39. 10.1016/j.nbd.2019.10456810.1016/j.nbd.2019.104568 ↗
40. 10.1111/acel.1279010.1111/acel.12790 ↗
41. 10.1517/14740338.2016.114074310.1517/14740338.2016.1140743 ↗
42. 10.4103/1673-5374.32732810.4103/1673-5374.327328 ↗
43. 10.1016/j.jconrel.2016.04.03810.1016/j.jconrel.2016.04.038 ↗
44. 10.1021/acsnano.9b0180810.1021/acsnano.9b01808 ↗
45. 10.1021/acsnano.8b0378510.1021/acsnano.8b03785 ↗
46. 10.3109/1061186X.2014.88807010.3109/1061186X.2014.888070 ↗
47. 10.1016/j.biomaterials.2016.08.01710.1016/j.biomaterials.2016.08.017 ↗
48. 10.1016/j.apmt.2022.10141210.1016/j.apmt.2022.101412 ↗
49. 10.1161/circ.132.suppl_3.1992210.1161/circ.132.suppl_3.19922 ↗
50. 10.1038/cdd.2016.710.1038/cdd.2016.7 ↗
51. 10.1161/circ.132.suppl_3.1992210.1161/circ.132.suppl_3.19922 ↗
52. Pechlaner C. · BMJ · 1997 · 314 · 155110.1136/bmj.314.7093.1551 ↗
53. 10.1007/s00604-018-2761-210.1007/s00604-018-2761-2 ↗
54. 10.1155/2016/475975010.1155/2016/4759750 ↗
55. 10.18632/oncotarget.2352710.18632/oncotarget.23527 ↗
56. 10.1080/10826076.2017.132028910.1080/10826076.2017.1320289 ↗
57. 10.7150/thno.4090810.7150/thno.40908 ↗
58. 10.3389/fneur.2020.59467210.3389/fneur.2020.594672 ↗
59. 10.1111/cns.1362010.1111/cns.13620 ↗
60. 10.1161/STROKEAHA.112.65965610.1161/STROKEAHA.112.659656 ↗
61. 10.3389/fimmu.2019.0123610.3389/fimmu.2019.01236 ↗
62. 10.1016/j.nbd.2019.10456810.1016/j.nbd.2019.104568 ↗
63. 10.1016/j.bbi.2011.10.00510.1016/j.bbi.2011.10.005 ↗
64. 10.1016/j.yfrne.2012.08.00610.1016/j.yfrne.2012.08.006 ↗
65. 10.1016/S0140-6736(16)30307-510.1016/S0140-6736(16)30307-5 ↗
66. 10.1111/cen.1383710.1111/cen.13837 ↗
67. 10.1002/glia.2263310.1002/glia.22633 ↗
68. 10.1083/jcb.20170906910.1083/jcb.201709069 ↗
69. 10.1007/s11064-018-2520-010.1007/s11064-018-2520-0 ↗
70. 10.3389/fncel.2018.0010610.3389/fncel.2018.00106 ↗
71. 10.1007/s12975-017-0554-210.1007/s12975-017-0554-2 ↗
72. 10.1161/str.49.suppl_1.WP25010.1161/str.49.suppl_1.WP250 ↗
73. 10.1016/j.mri.2016.04.01610.1016/j.mri.2016.04.016 ↗
74. 10.1007/s00701-011-1122-210.1007/s00701-011-1122-2 ↗
75. 10.1089/neu.2008.068610.1089/neu.2008.0686 ↗
76. 10.1111/j.1750-3639.2000.tb00248.x10.1111/j.1750-3639.2000.tb00248.x ↗
77. 10.1016/j.neuron.2017.07.03010.1016/j.neuron.2017.07.030 ↗
78. 10.1038/jcbfm.1990.6010.1038/jcbfm.1990.60 ↗